Overview

Several types of anti-obesity drugs have been developed to investigate their role in the treatment of obesity. ADME (absorption, distribution, metabolism, and excretion) study is an important part of the evaluation of the potential safety and efficacy of these anti-obesity drugs. The testing of potential drugs provides valuable information for optimizing the pharmacological properties of the drug, determining dosage to enhance therapeutic efficacy, and minimizing risk. Protheragen offers a comprehensive ADME study service of anti-obesity drugs, using a variety of sensitive bioanalytical methods for the relevant assays. Relying on its many years of service experience, we provide customized experimental solutions to facilitate the research process of anti-obesity drugs.

ADME Research Solutions Tailored for Anti-Obesity Drug Research

Our comprehensive ADME research service for anti-obesity drugs includes anti-obesity drug development, experimental design, ADME studies, and data analysis to help analyze the properties of drug candidates and their interactions. Our experienced ADME team has strong testing and analytical capabilities to complete various flexible tests and help clients make critical decisions in drug discovery and research. Specific services include the following:

• Anti-Obesity Drug Development

  We develop anti-obesity drugs against a variety of targets (including various Enzymes, Hormones, Receptors, Metabolic Modulators, etc.). Firstly, we predict the interaction and binding strength, drug-like properties, toxicology, etc., of potential anti-obesity drugs and targets through computer simulation and computation. Molecular docking, molecular dynamics simulations, and others provide valuable information for the design and optimization of anti-obesity drugs. Then we screen or synthesize various natural products, peptides, small molecules, other compounds, etc., and analyze their anti-obesity effects and safety using comprehensive preclinical experiments.

• In Vitro ADME Analysis

  Under in vitro conditions (liver, cell cultures, microsomal fractions of other tissues) we study and evaluate the absorption, distribution, metabolism, and excretion of various potential anti-obesity drugs. In vitro ADME analysis has a crucial role in anti-obesity drug development. It helps screen anti-obesity drug candidate molecules with favorable ADME properties and provides an important basis for the safety and efficacy assessment of drugs. In addition to this, it also helps to improve the structure of anti-obesity drugs to enhance their absorption, distribution, metabolism, and excretion properties. We are equipped with a wide range of state-of-the-art instrumentation, which allows us to provide reliable data to support high-throughput screening and research of anti-obesity drugs.

  • Stability assays (hepatocyte, plasma, microsomal)
  • Kinetic solubility
  • Metabolic pathway identification
  • Metabolite identification
  • Cytochrome P450 (CYP) response phenotyping
  • CYP induction assay
  • CYP inhibition assay
  • Uridine diphosphate glucuronosyltransferase (UGT) inhibition assay
  • Protein binding studies (plasma proteins, microsomal proteins, histones)
  • High-throughput ADME screening
  • Permeability and transporter protein analysis
  • Others

• In Vivo Studies

  Having learned about the in vitro ADME properties of potential anti-obesity drugs, we also conduct in vivo ADME assays. This analysis is performed in a variety of models, including Mice, Rats, Dogs, Pigs, etc. The assays include liquid chromatography with tandem mass spectrometry (LC-MS-MS), reverse transcription polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), isotope labeling, and so on. The full range of analyses and more accurate data help to understand how drugs are absorbed, distributed, metabolized, and excreted in the organism.

  • Tissue distribution
  • Biliary excretion
  • Metabolite identification
  • Others

Workflow

We provide complete solutions and reliable experimental data to help gain deeper insights into anti-obesity drug development.

Applications

• ADME studies provide valuable information for the development of safer and more effective anti-obesity therapies.
• Understanding how anti-obesity drugs are absorbed, distributed, metabolized, and excreted through ADME studies helps to better predict their behavior in the body and provides valuable information for optimizing formulation and dosage-related studies.
• ADME studies are used for the analysis of multiple drug interactions in combination therapies.

Advantages

• We have a team with extensive experience in ADME assays to support the rapid conduct of assay projects and the delivery of high-quality results.
• Our ADME assay process has been validated to ensure the accuracy and reliability of the data.
• We design tailor-made protocols to meet the needs of our clients to support the anti-obesity drug discovery process.

Other Cutting-edge Services to Meet a Wide Range of Obesity Research Needs

While accelerating the development of anti-obesity therapies, we have also broadened our services to provide comprehensive obesity risk assessment, diagnostic testing services, and obesity prediction services. In addition, we help detect obesity-related biomarkers, microbiomes, and pathological features in individual samples. Personalized weight loss and weight management services are also what we specialize in. We are familiar with the specificities of each research program and offer flexible solutions based on our extensive practical experience.

Publication Data

Frequently Asked Questions

What does the in vitro ADME study mean?

ADME refers to absorption, distribution, metabolism, and excretion, which is a necessary research process in the development of anti-obesity drugs.

• Absorption is the process by which a drug enters the body circulation from the site of administration, in which the degree and speed of absorption directly affect the effective concentration and therapeutic effect of the anti-obesity drug. We simulate drug absorption and predict the speed of drug absorption through cell culture and cell membrane channel models.
• After entering the circulation, anti-obesity drugs will be distributed to various tissues and organs. We conduct in vitro ADME studies of anti-obesity drugs through microdialysis, cellular experiments, etc., to assess the distribution characteristics of drugs and predict in vivo distribution.
• Drugs are metabolized through reactions including oxidation, reduction, hydrolysis, etc., and converted into various types of metabolites. This process affects the efficacy of the drug and may trigger adverse reactions. We perform in vitro metabolic analyses by metabolic pathway analysis and enzyme activity tests to study the metabolic properties, metabolic rate, and metabolites of anti-obesity drugs.
• Anti-obesity drugs and their metabolites need to be excreted from the body to maintain drug homeostasis. The route and rate of their excretion affect the therapeutic efficacy. We assess the excretion characteristics, rates, and pathways of potential anti-obesity drugs by glomerular filtration, intestinal motility modeling, and others.

What are the advantages of in vitro ADME analysis?

In vitro ADME analyses offer various advantages over animal studies. It is simpler and faster than animal studies. The analysis predicts the ADME properties of potential anti-obesity drugs at an early stage, providing important information for drug development and saving experimental time. It also predicts the absorption and metabolism behavior of potential anti-obesity drugs in vivo more accurately through cellular and enzyme systems, reducing the risk of drug development.

Protheragen is ready to serve and provide a one-stop ADME service to support anti-obesity drug discovery and research. Welcome to contact us for more detailed testing information if you have a need or interest in this area. Our staff will respond as soon as possible and provide you with a service.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• DMPK Study of Anti-Obesity Drugs